Sudden cardiac death (SCD) is by definition unexpected and cardiac in nature. The investigation is almost invariably performed by a forensic pathologist. Under these circumstances the role of the forensic pathologist is twofold: (1.) to determine rapidly and efficiently the cause and manner of death and (2.) to initiate a multidisciplinary process in order to prevent further deaths in existing family members. If the death is determined to be due to "natural" causes the district attorney in charge often refuses further examinations. However, additional examinations, i.e. extensive histopathological investigations and/or molecular genetic analyses, are necessary in many cases to clarify the cause of death. The Swiss Society of Legal Medicine created a multidisciplinary working group together with clinical and molecular geneticists and cardiologists in the hope of harmonising the approach to investigate SCD. The aim of this paper is to close the gap between the Swiss recommendations for routine forensic post-mortem cardiac examination and clinical recommendations for genetic testing of inherited cardiac diseases; this is in order to optimise the diagnostic procedures and preventive measures for living family members. The key points of the recommendations are (1.) the forensic autopsy procedure for all SCD victims under 40 years of age, (2.) the collection and storage of adequate samples for genetic testing, (3.) communication with the families, and (4.) a multidisciplinary approach including cardiogenetic counselling.

No abstract

(2015). Acute toxicity profile of tolperisone in overdose: Observational poison centre-based study. Clinical Toxicology, 53 (5) The paper is written in UK English.Running head: Acute toxicity profile of tolperisone in overdose.Word count (excluding references, figure, and abstract): 2075References: 29 Grant or other financial support:The present work was supported entirely by internal resources of the participating study sites. ABSTRACTIntroduction: Tolperisone is a centrally-acting muscle relaxant that acts by blocking

We present the case of a 71 year old Swiss woman with a symptomatic rheumatic arthritis whose rheumatologist started a therapy with methotrexate. While the symptoms disappeared completely, the woman died about two months later suddenly. By then she got a cumulative dose of 160 mg. The forensic post-mortem examination showed a fibrosing alveolitis. If respiratory symptoms appear under methotrexat regimen therapy, immediate stopping the medication could be life-saving. In accordance to the chest x-ray a cortisone therapy can be established.